The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Read the entire package insert before using this ...

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...

Approval of the topical aryl hydrocarbon receptor agonist was supported by the pivotal ADORING studies. In the ...

The approval was based on data from 2 multicenter, randomized, double-blind, vehicle-controlled trials, ADORING 1 and ADORING 2.

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis. Ahead ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

According to newly published research, the exposure to nature provided by the Re-Connecting Nature forest microbe extract has ...

Monday announced that the U.S. Food and Drug Administration (FDA) has approved Vtama (tapinarof) cream, an aryl ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) with or without asthma and allergic rhinitis in young children.

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to ...